These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 451340)

  • 1. Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity.
    Powis G; Ames MM; Kovach JS
    Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):559-69. PubMed ID: 451340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic conversion of indicine N-oxide to indicine in rabbits and humans.
    Powis G; Ames MM; Kovach JS
    Cancer Res; 1979 Sep; 39(9):3564-70. PubMed ID: 476682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid.
    Wang YP; Yan J; Fu PP; Chou MW
    Toxicol Lett; 2005 Mar; 155(3):411-20. PubMed ID: 15649625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indicine-N-oxide: a new antitumor agent.
    Poster DS; Bruno S; Penta J; Macdonald JS
    Cancer Treat Rep; 1981; 65(1-2):53-6. PubMed ID: 6939484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gas chromatographic mass spectrometric analysis of the new antitumor drug indicine-N-oxide utilizing a novel reaction accompanying trimethylsilylation.
    Evans JV; Peng A; Nielsen CJ
    Biomed Mass Spectrom; 1979 Jan; 6(1):38-43. PubMed ID: 427260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of indicine N-oxide in mice and monkeys.
    El Dareer SM; Tillery KF; Lloyd HH; Hill DL
    Cancer Treat Rep; 1982 Jan; 66(1):183-6. PubMed ID: 7053256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Oxide reduction by hemoglobin, cytochrome C and ferrous ions.
    Powis G; DeGraw CL
    Res Commun Chem Pathol Pharmacol; 1980 Oct; 30(1):143-50. PubMed ID: 6254119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic activation of retronecine and retronecine N-oxide - formation of DHP-derived DNA adducts.
    Yan J; Xia Q; Chou MW; Fu PP
    Toxicol Ind Health; 2008 Apr; 24(3):181-8. PubMed ID: 18842697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P-450.
    Powis G; Wincentsen L
    Biochem Pharmacol; 1980 Feb; 29(3):347-51. PubMed ID: 6767485
    [No Abstract]   [Full Text] [Related]  

  • 10. Formation of DHP-derived DNA adducts from metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, heliotrine.
    Xia Q; Yan J; Chou MW; Fu PP
    Toxicol Lett; 2008 May; 178(2):77-82. PubMed ID: 18395999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron-EDTA stimulated reduction of indicine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat.
    Powis G; Svingen BA; Degraw C
    Biochem Pharmacol; 1982 Feb; 31(3):293-9. PubMed ID: 6280724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indicine-N-oxide: the antitumor principle of Heliotropium indicum.
    Kugelman M; Liu WC; Axelrod M; McBride TJ; Rao KV
    Lloydia; 1976; 39(2-3):125-8. PubMed ID: 948236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of spironolactone treatment on the cytochrome P450-mediated metabolism of the pyrrolizidine alkaloid senecionine by hepatic microsomes from rats and guinea pigs.
    Chung WG; Buhler DR
    Toxicol Appl Pharmacol; 1994 Aug; 127(2):314-9. PubMed ID: 8048076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of indicine N-oxide (INDI) in patients with advanced colorectal carcinoma.
    Nichols WC; Moertel CG; Rubin J; Schutt AJ; Britell JC
    Cancer Treat Rep; 1981; 65(3-4):337-9. PubMed ID: 7016321
    [No Abstract]   [Full Text] [Related]  

  • 15. Indicine N-oxide binds to tubulin at a distinct site and inhibits the assembly of microtubules: a mechanism for its cytotoxic activity.
    Appadurai P; Rathinasamy K
    Toxicol Lett; 2014 Feb; 225(1):66-77. PubMed ID: 24300171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of indicine N-oxide in patients with advanced cancer.
    Ohnuma T; Sridhar KS; Ratner LH; Holland JF
    Cancer Treat Rep; 1982 Jul; 66(7):1509-15. PubMed ID: 7093966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of indicine N-oxide in refractory acute leukemia.
    Letendre L; Smithson WA; Gilchrist GS; Burgert EO; Hoagland CH; Ames MM; Powis G; Kovach JS
    Cancer; 1981 Feb; 47(3):437-41. PubMed ID: 7013959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans.
    Kovach JS; Ames MM; Powis G; Moertel CG; Hahn RG; Creagan ET
    Cancer Res; 1979 Nov; 39(11):4540-4. PubMed ID: 498086
    [No Abstract]   [Full Text] [Related]  

  • 19. Indicine N-oxide: clinical use of a pyrrolizidine alkaloid.
    King SA; Suffness M; Leyland-Jones B; Hoth DF; O'Dwyer PJ
    Cancer Treat Rep; 1987 May; 71(5):517-23. PubMed ID: 3552221
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of flavin-containing monooxygenase in the N-oxidation of the pyrrolizidine alkaloid senecionine.
    Williams DE; Reed RL; Kedzierski B; Ziegler DM; Buhler DR
    Drug Metab Dispos; 1989; 17(4):380-6. PubMed ID: 2571476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.